Environmental and lifestyle factors, such as certain foods and infections, may trigger onset of psoriasis and account for approximately 30% of the risk of the condition in people with a genetic preposition, research presented in London shows.
Psoriasis Gene to Clinic 2017
Psoriasis has long been linked with poor nutrition, high body mass index and metabolic disorders. New research suggests a reduced sense of taste and smell, caused by inflammation, may explain why.
Psoriasis patients carrying a specific gene experience a significantly better early response to ustekinumab, but are less likely to achieve high rates of response to anti-TNFs.
The spleen may have a role in driving the higher rate of cardiovascular disease seen in psoriasis patients through a spleen–atherosclerotic axis, suggests research presented at a meeting in London.
Switching from adalimumab to etanercept or vice versa after interruption can improve treatment response, data presented in London suggests.
Phase three trials of the selective IL-23 blocker risankizumab are replicating the promising results achieved by phase two trials for psoriasis, researchers report in London.
Secukinumab has been shown to be effective for the treatment of moderate-to-severe plaque psoriasis in hard-to-treat patients who failed anti-TNFa treatment, researchers report in London.
Adding caffeine to topical skin treatments would be a simple way to reduce inflammation in patients with atopic dermatitis and psoriasis, suggests a review presented at the Psoriasis: From Gene to Clinic International Congress, which took place in London this week.
Patients with psoriasis are more likely than the general population to receive a diagnosis of malignant lymphoma. Why? Cutaneous T-cell lymphoma is misdiagnosed as psoriasis and can also be mistaken for atopic dermatitis due to similarities in the skin manifestation.
Experts from around the world will gather in London at the Psoriasis from Gene to Clinic Congress to present and discuss the most current developments in the understanding of psoriasis and the evidence that will steer future clinical decision making. Watch here for highlights.